58 related articles for article (PubMed ID: 10854696)
1. Mouse receptor-activity-modifying proteins 1, -2 and -3: amino acid sequence, expression and function.
Husmann K; Sexton PM; Fischer JA; Born W
Mol Cell Endocrinol; 2000 Apr; 162(1-2):35-43. PubMed ID: 10854696
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding.
Kusano S; Kukimoto-Niino M; Hino N; Ohsawa N; Okuda K; Sakamoto K; Shirouzu M; Shindo T; Yokoyama S
Protein Sci; 2012 Feb; 21(2):199-210. PubMed ID: 22102369
[TBL] [Abstract][Full Text] [Related]
3. Modulation of osteoclastogenesis through adrenomedullin receptors on osteoclast precursors: initiation of differentiation by asymmetric cell division.
Kukita T; Hiura H; Gu JY; Zhang JQ; Kyumoto-Nakamura Y; Uehara N; Murata S; Sonoda S; Yamaza T; Takahashi I; Kukita A
Lab Invest; 2021 Nov; 101(11):1449-1457. PubMed ID: 34611305
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the structure of RAMP1 by mutagenesis and molecular modeling.
Simms J; Hay DL; Wheatley M; Poyner DR
Biophys J; 2006 Jul; 91(2):662-9. PubMed ID: 16632510
[TBL] [Abstract][Full Text] [Related]
5. Modifying proteins with RNA.
Song Y
Nat Chem Biol; 2023 Oct; 19(10):1172. PubMed ID: 37749349
[No Abstract] [Full Text] [Related]
6. Functional Analysis and Tissue-Specific Expression of Calcitonin and CGRP with RAMP-Modulated Receptors CTR and CLR in Chickens.
Huang T; Su J; Wang X; Shi N; Zhang X; He J; Li J; Zhang J; Wang Y
Animals (Basel); 2024 Mar; 14(7):. PubMed ID: 38612299
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins.
Kotliar IB; Lorenzen E; Schwenk JM; Hay DL; Sakmar TP
Pharmacol Rev; 2023 Jan; 75(1):1-34. PubMed ID: 36757898
[TBL] [Abstract][Full Text] [Related]
8. A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond.
Garelja ML; Hay DL
Headache; 2022 Oct; 62(9):1093-1104. PubMed ID: 36226379
[TBL] [Abstract][Full Text] [Related]
9. Amylin Pharmacology in Alzheimer's Disease Pathogenesis and Treatment.
Corrigan RR; Piontkivska H; Casadesus G
Curr Neuropharmacol; 2022; 20(10):1894-1907. PubMed ID: 34852745
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterisation of mouse calcitonin and calcitonin receptor-like receptors reveals differences compared with human receptors.
Garelja ML; Bower RL; Brimble MA; Chand S; Harris PWR; Jamaluddin MA; Petersen J; Siow A; Walker CS; Hay DL
Br J Pharmacol; 2022 Feb; 179(3):416-434. PubMed ID: 34289083
[TBL] [Abstract][Full Text] [Related]
11. A selective role for receptor activity-modifying proteins in subchronic action of the amylin selective receptor agonist NN1213 compared with salmon calcitonin on body weight and food intake in male mice.
Arrigoni S; Le Foll C; Cabak A; Lundh S; Raun K; John LM; Lutz TA
Eur J Neurosci; 2021 Aug; 54(3):4863-4876. PubMed ID: 34189795
[TBL] [Abstract][Full Text] [Related]
12. Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.
Vázquez R; Riveiro ME; Berenguer-Daizé C; O'Kane A; Gormley J; Touzelet O; Rezai K; Bekradda M; Ouafik L
Front Oncol; 2020; 10():589218. PubMed ID: 33489885
[TBL] [Abstract][Full Text] [Related]
13. Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's disease.
Soudy R; Patel A; Fu W; Kaur K; MacTavish D; Westaway D; Davey R; Zajac J; Jhamandas J
Alzheimers Dement (N Y); 2017 Jan; 3(1):44-56. PubMed ID: 29067318
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effects of exogenous adrenomedullin and CGRP in Ramp and Calcrl deficient mice.
Pawlak JB; Wetzel-Strong SE; Dunn MK; Caron KM
Peptides; 2017 Feb; 88():1-7. PubMed ID: 27940069
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2).
Weston C; Lu J; Li N; Barkan K; Richards GO; Roberts DJ; Skerry TM; Poyner D; Pardamwar M; Reynolds CA; Dowell SJ; Willars GB; Ladds G
J Biol Chem; 2015 Sep; 290(38):23009-22. PubMed ID: 26198634
[TBL] [Abstract][Full Text] [Related]
16. Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner.
Barrick CJ; Lenhart PM; Dackor RT; Nagle E; Caron KM
J Mol Cell Cardiol; 2012 Jan; 52(1):165-74. PubMed ID: 22100352
[TBL] [Abstract][Full Text] [Related]
17. Neuronal receptor activity-modifying protein 1 promotes energy expenditure in mice.
Zhang Z; Liu X; Morgan DA; Kuburas A; Thedens DR; Russo AF; Rahmouni K
Diabetes; 2011 Apr; 60(4):1063-71. PubMed ID: 21357463
[TBL] [Abstract][Full Text] [Related]
18. A role for protein kinase C-dependent upregulation of adrenomedullin in the development of morphine tolerance in male rats.
Hong Y; Wang D; Chabot JG; Ma W; Chen P; Quirion R
J Neurosci; 2010 Sep; 30(37):12508-16. PubMed ID: 20844145
[TBL] [Abstract][Full Text] [Related]
19. Identification of RL-TGR, a coreceptor involved in aversive chemical signaling.
Cohen SP; Haack KK; Halstead-Nussloch GE; Bernard KF; Hatt H; Kubanek J; McCarty NA
Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12339-44. PubMed ID: 20566865
[TBL] [Abstract][Full Text] [Related]
20. Class II G protein-coupled receptors and their ligands in neuronal function and protection.
Martin B; Lopez de Maturana R; Brenneman R; Walent T; Mattson MP; Maudsley S
Neuromolecular Med; 2005; 7(1-2):3-36. PubMed ID: 16052036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
